MX2013002554A - Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg). - Google Patents

Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).

Info

Publication number
MX2013002554A
MX2013002554A MX2013002554A MX2013002554A MX2013002554A MX 2013002554 A MX2013002554 A MX 2013002554A MX 2013002554 A MX2013002554 A MX 2013002554A MX 2013002554 A MX2013002554 A MX 2013002554A MX 2013002554 A MX2013002554 A MX 2013002554A
Authority
MX
Mexico
Prior art keywords
erythropoietin
residue
ethylene glycol
cation exchange
pegylated erythropoietin
Prior art date
Application number
MX2013002554A
Other languages
English (en)
Other versions
MX342444B (es
Inventor
Wolfgang Kuhne
Roberto Falkenstein
Wolfgang Koehnlein
Schurig Hartmut
Schurig Sibylle
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013002554A publication Critical patent/MX2013002554A/es
Publication of MX342444B publication Critical patent/MX342444B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente invención se reporta un método para la purificación de una proteína que comprende eritropoyetina y un residuo individual de poli(etilenglicol) de subproductos de reacción o un material de partida sin reaccionar por medio de un método de cromatografía de intercambio catiónico. Se ha descubierto que al emplear un material de cromatografía de intercambio catiónico SP Sephacryl S 500 HRMR acondicionado a una conductividad de 21 mS/cm y una elución de gradiente lineal, una proteína de fusión de eritropoyetina y un residuo individual de poli(etilenglicol) se pueden obtener en un paso individual con alta pureza y alto rendimiento.
MX2013002554A 2010-09-14 2011-09-13 Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg). MX342444B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10176616 2010-09-14
PCT/EP2011/065888 WO2012035037A1 (en) 2010-09-14 2011-09-13 Method for purifying pegylated erythropoietin

Publications (2)

Publication Number Publication Date
MX2013002554A true MX2013002554A (es) 2013-05-28
MX342444B MX342444B (es) 2016-09-29

Family

ID=43385653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002554A MX342444B (es) 2010-09-14 2011-09-13 Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).

Country Status (15)

Country Link
US (4) US20120197007A1 (es)
EP (1) EP2616101B1 (es)
JP (1) JP5735650B2 (es)
KR (1) KR101578586B1 (es)
CN (1) CN103118708B (es)
BR (1) BR112013005890B1 (es)
CA (1) CA2808748C (es)
DK (1) DK2616101T3 (es)
ES (1) ES2500048T3 (es)
HK (1) HK1181661A1 (es)
MX (1) MX342444B (es)
PL (1) PL2616101T3 (es)
RU (1) RU2566267C2 (es)
SI (1) SI2616101T1 (es)
WO (1) WO2012035037A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
DE102016210647B3 (de) 2016-06-15 2017-09-14 Schaeffler Technologies AG & Co. KG Keilkupplung-Synchronisation
EP3484911B1 (en) * 2016-07-15 2020-11-04 H. Hoffnabb-La Roche Ag Method for purifying pegylated erythropoietin
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
ES2905105T3 (es) 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
HRP20220388T1 (hr) 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
CN111741770A (zh) * 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DK0452484T3 (da) 1989-11-06 1996-10-14 Cell Genesys Inc Fremstilling af proteiner ved homolog rekombination
KR0176693B1 (ko) 1989-12-22 1999-04-01 레지널드 디. 쇼트보그; 제롬 반 쥘렌 조절요소를 사용한 내인성 유전자의 발현을 변형시키는 방법
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
DE4118912C1 (es) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE225801T1 (de) 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2002540065A (ja) 1999-01-29 2002-11-26 アムジェン インコーポレーテッド Ｇｃｓｆコンジュゲート
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US20050008649A1 (en) 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
US20120172299A1 (en) 2008-09-23 2012-07-05 F. Hoffmann-La Roche Ag Purification of erythropoietin
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs

Also Published As

Publication number Publication date
US20170008941A1 (en) 2017-01-12
BR112013005890A2 (pt) 2020-04-14
JP5735650B2 (ja) 2015-06-17
US10273277B2 (en) 2019-04-30
US20140163207A1 (en) 2014-06-12
RU2566267C2 (ru) 2015-10-20
US20210094993A1 (en) 2021-04-01
WO2012035037A1 (en) 2012-03-22
SI2616101T1 (sl) 2014-10-30
ES2500048T3 (es) 2014-09-29
KR20130073964A (ko) 2013-07-03
CA2808748A1 (en) 2012-03-22
EP2616101B1 (en) 2014-07-09
PL2616101T3 (pl) 2015-01-30
BR112013005890B1 (pt) 2022-02-08
DK2616101T3 (da) 2014-08-04
CN103118708B (zh) 2015-08-26
HK1181661A1 (en) 2013-11-15
US20120197007A1 (en) 2012-08-02
CA2808748C (en) 2018-09-11
EP2616101A1 (en) 2013-07-24
CN103118708A (zh) 2013-05-22
RU2013113724A (ru) 2014-10-20
JP2013537208A (ja) 2013-09-30
MX342444B (es) 2016-09-29
KR101578586B1 (ko) 2015-12-17

Similar Documents

Publication Publication Date Title
MX342444B (es) Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).
MY172991A (en) Interleukin-2 muteins for the expansion of t-regulatory cells
IL227691A0 (en) Creation and purification of 29 – il
MY186089A (en) Chromatographic processes and purified compounds thereof
RU2014148136A (ru) Композиции т-клеток с недостаточностью рецепторов т-клеток
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
TW200716557A (en) Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
MY156181A (en) Method and system for producing high-purity hydrogen chloride
MX2013001447A (es) Metodo de produccion y purificacion de una sialiltransferasa soluble activa.
CY1116963T1 (el) Μεθοδος για καθαρισμο ανασυνδυασμενης fsh
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
MX342235B (es) Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
WO2014178078A3 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
BRPI0507233A (pt) processo de produção de polipeptìdeo heterólogo em e.coli
NZ719881A (en) Plant cytochrome p450
MX349596B (es) Metodo para la expresion de polipeptidos usando acidos nucleicos modificados.
EP1967242A4 (en) PROCESS FOR THE INDUSTRIAL PRODUCTION OF DIALKYL CARBONATE AND DIOL
CN103113227B (zh) 3-甲氧基丙烯酸甲酯的制备方法
MY160954A (en) Agomelatine intermediates and preparation method thereof
MD20160071A2 (ro) Procedeu nou de sinteză a agomelatinei
NZ707753A (en) Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
FR2985998B1 (fr) Procede de production d'acrylate de 2-octyle par transesterification
MX2017009714A (es) Metodos para producir compuesto de pirazin carboxamida e intermediario sintetico del mismo.
MX2018016033A (es) Metodo para purificar eritropoyetina pegilada.

Legal Events

Date Code Title Description
FG Grant or registration